The Healthcare, Life Sciences, and Private Equity teams guided Gannet BioChem, backed by Boston-based private equity firm Ampersand Capital Partners, on the acquisition of Laysan Bio, a life sciences company based in Arab, Alabama. The acquisition strengthens Gannet BioChem’s capabilities across activated polymer technologies, including PEG reagents and bioconjugation while enhancing its ability to support partners from early development through GMP manufacturing.
With over 30 years of expertise, Gannet BioChem is a leading specialty CDMO specializing in the development, scaling, and manufacturing of polyethylene glycol (PEG) reagents—essential components in advanced biopharmaceutical and therapeutic products. Operating from a state-of-the-art 124,000 sq. ft. FDA-inspected facility in Huntsville, Alabama, Gannet BioChem delivers end-to-end GMP production, supporting clinical and commercial therapeutics. With a highly experienced team, flexible production capabilities, and a commitment to quality, Gannet BioChem provides reliable, innovative solutions to meet the evolving needs of the global biopharmaceutical industry.
The Goodwin team was led by Jim Barrett, Eric Carlson, Jon Berke, Ryan Peloquin, Travis Salters, Shannyn Henke, Kelly Song, Jacob Margolis, Timothy Holahan, Austin Jones, Malhar Naik, Jacqueline Klosek, Richard Matheny, Gozde Guckaya, Andy Sucoff, Nate Brodeur, Daniel Karelitz, Nicole Brock, Matthew Wetzel, Julie Tibbets, with invaluable assistance from Kerri Finn and Amanda Fernandes.
For more information on the deal, please read the press release.